Cancer Letters
Volume 290, Issue 2 , Pages 182-191 , 28 April 2010

Celastrol, a novel HSP90 inhibitor, depletes Bcr–Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation

  • Zhongzheng Lu

      Affiliations

    • Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan Road II, Guangzhou 510089, People’s Republic of China
    • ,
  • Yanli Jin

      Affiliations

    • Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan Road II, Guangzhou 510089, People’s Republic of China
    • ,
  • Lin Qiu

      Affiliations

    • Harbin Institute of Hematology and Oncology, Harbin, People’s Republic of China
    • ,
  • Yingrong Lai

      Affiliations

    • Department of Pathology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan Road II, Guangzhou 510089, People’s Republic of China
    • ,
  • Jingxuan Pan

      Affiliations

    • Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan Road II, Guangzhou 510089, People’s Republic of China
    • Corresponding Author InformationCorresponding author. Tel./fax: +86 20 8733 2788.

Received 10 July 2009 ,Revised 5 September 2009 ,Accepted 7 September 2009.

References 

  1. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68:3077–3080
  2. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007;21:3214–3231
  3. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006;66:10959–10966
  4. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR–ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 1995;15:5531–5541
  5. Druker BJ, Guilhot F, O’Brien S, Larson RA. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the five-year update from the IRIS study. J. Clin. Oncol. 2006;24:18S;(Abstract)
  6. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J. Clin. Invest. 2009;119:1109–1123
  7. Hofmann WK, Jones LC, Lemp NA. S. de Vos, H. Gschaidmeier, D. Hoelzer, O.G. Ottmann, and H.P. Koeffler, Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR–ABL gene mutation. Blood. 2002;99:1860–1862
  8. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690–698
  9. Gambacorti-Passerini C, Gambacorti-Passerini C, le Coutre P, Zucchetti M, D’Incalci M. Binding of imatinib by alpha(1)-acid glycoprotein. Blood. 2002;100:367–368
  10. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739–3745
  11. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science. 2001;293:876–880
  12. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–2196
  13. Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation. Expert. Rev. Anticancer Therap. 2008;8:1387–1398
  14. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006;354:2531–2541
  15. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, et al. A non-ATP-competitive inhibitor of BCR–ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA. 2005;102:1992–1997
  16. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR–ABL inhibitors. Nat. Rev. Drug. Discov. 2007;6:834–848
  17. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, et al. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia. 2008;22:1191–1199
  18. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, et al. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006;107:2501–2506
  19. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR–ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002;100:3041–3044
  20. Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR–ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood. 2007;110:678–685
  21. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr–Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003;63:5126–5135
  22. Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, et al. Triptolide inhibits Bcr–Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin. Cancer Res. 2009;15:1686–1697
  23. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer. 2005;5:761–772
  24. Nimmanapalli R, O’Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr–Abl levels and induces apoptosis and differentiation of Bcr–Abl-positive human leukemic blasts. Cancer Res. 2001;61:1799–1804
  25. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10:321–330
  26. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Therapeut. 2008;7:162–170
  27. Qiu L, Wang XD, Yu BH, Lu RZ, Ge F, Wang XL, et al. Effect of a novel tyrosine kinase inhibitor HHGV678 on growth inhibition of Bcr–Abl wild type and IM-resistant cell lines in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16:1039–1043
  28. Jin Y, Chen Q, Shi X, Lu Z, Cheng C, Lai Y, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 2009;100:1335–1343
  29. Jin Y, Chen Q, Shi X, Lu Z, Cheng C, Lai Y, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 2009;
  30. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007;109:315–322
  31. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106:2865–2870
  32. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese, Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006;66:4758–4765
  33. Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell. 2007;130:769–774
  34. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 2007;13:353–361
  35. Tao XL, Sun Y, Dong Y, Xiao YL, Hu DW, Shi YP, et al. A prospective, Controlled, double-blind, cross-over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis. Chin. Med. J. Engl. 1989;102:327–332
  36. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood. 2007;109:2727–2735
  37. Abbas S, Bhoumik A, Dahl R, Vasile S, Krajewski S, Cosford ND, et al. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin. Cancer Res. 2007;13:6769–6778

PII: S0304-3835(09)00573-4

doi: 10.1016/j.canlet.2009.09.006

Cancer Letters
Volume 290, Issue 2 , Pages 182-191 , 28 April 2010

Article Tools

* Image Usage & Resolution